Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 6,000 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak Azamian sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Tarsus Pharmaceuticals Stock Performance

TARS stock traded up $0.36 during midday trading on Tuesday, hitting $82.33. The company’s stock had a trading volume of 1,446,636 shares, compared to its average volume of 639,103. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The stock has a market cap of $3.49 billion, a price-to-earnings ratio of -40.76 and a beta of 0.74. The stock’s 50-day moving average price is $76.34 and its 200 day moving average price is $59.98. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The business had revenue of $118.70 million during the quarter, compared to the consensus estimate of $114.22 million. On average, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TARS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. The Goldman Sachs Group restated a “neutral” rating and issued a $51.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 6th. Barclays began coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective on the stock. Wall Street Zen raised Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Guggenheim lifted their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $79.86.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after buying an additional 339 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Tarsus Pharmaceuticals by 0.6% during the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after acquiring an additional 339 shares in the last quarter. Creative Planning boosted its holdings in shares of Tarsus Pharmaceuticals by 3.3% in the third quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after purchasing an additional 393 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in Tarsus Pharmaceuticals by 6.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,626 shares of the company’s stock worth $349,000 after purchasing an additional 505 shares in the last quarter. Finally, Quarry LP grew its stake in Tarsus Pharmaceuticals by 20.0% in the first quarter. Quarry LP now owns 3,599 shares of the company’s stock worth $185,000 after purchasing an additional 599 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.